Synplogen Co., a synthetic biology startup spun out of Kobe University’s Graduate School of Science, Technology and Innovation that provides custom DNA synthesis and Gene Therapy Biofoundry services, and Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a non-binding Memorandum of Understanding (“MOU”). Together, Synplogen and Ginkgo intend to accelerate the global development of DNA manufacturing and gene therapy platform services in Japan.
Ginkgo and Synplogen will explore global business collaboration opportunities for DNA manufacturing. Synplogen’s OGAB™ DNA synthesis services have the ability to synthesize DNA of various lengths up to 100 kbp. OGAB is also capable of complex DNA synthesis, with features such as a high/low guanine-cytosine content and repeat sequences.
Furthermore, Ginkgo and Synplogen will work to extend the reach of Ginkgo’s gene therapy services in Japan. Synplogen plans to collaborate by offering business development and marketing support to connect Ginkgo’s services with Japanese biotechnology and pharmaceutical companies. Ginkgo is prepared to utilize its end-to-end AAV gene therapy development platform, coupled with unique expertise in high-throughput design and synthesis optimization, to catalyze advancements in the Japanese bioeconomy.
“Japan has long been a leader in developing innovations for the bioeconomy,” said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. “We’re thrilled to partner with Synplogen as we seek to grow our cell and gene therapy service offerings in Japan as well as support the vibrant and innovative Japanese bioeconomy more broadly.”
“We are so honored that our DNA synthesis technology has been recognized by Ginkgo Bioworks, which is the global biofoundry leader,” said Kazuhiko Yamamoto, Representative Director and CEO of Synplogen. “Ginkgo’s services can play a crucial role in driving growth in Japan’s bioeconomy. We look forward to the practical impact of Ginkgo’s contributions, aligning well with our commitment to advancing innovative solutions for the Japanese biotech sector.”